CyBorD联合或不联合沙利度胺巩固治疗老年不适合移植多发性骨髓瘤患者的真实世界多中心回顾性分析
该回顾性多中心分析纳入155例70岁及以上新诊断多发性骨髓瘤患者,接受至少一周期CyBorD化疗。预先计划转换为VTD巩固治疗者中位EFS优于单纯CyBorD组。
核心结论
- 这是目前关于CyBorD在老年人群疗效的最大真实世界数据集,预先计划转换为VTD巩固治疗与更好的结局相关。
研究设计与样本
- 回顾性多中心真实世界分析,纳入新西兰三个中心共155例70岁及以上新诊断多发性骨髓瘤患者,均接受至少一周期CyBorD化疗。
临床怎么用
- CyBorD是老年不适合移植多发性骨髓瘤患者的有效前线化疗方案。
- 对于完成至少7周期治疗的患者,预先计划转换为VTD巩固治疗可能与更优的EFS相关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bortezomib in combination with cyclophosphamide and dexamethasone (CyBorD, is a well-established frontline chemotherapy regimen for patients with multiple myeloma, but prospective data on elderly non-transplant eligible patients is limited. A total of 155 patients aged 70 years or older with newly diagnosed multiple myeloma who received at least one cycle of CyBorD chemotherapy in three centres across New Zealand were evaluated. Partial response or better was achieved in 79·4%, of whom 52·9% achieved at least a very good partial response. After a median follow-up of 31·9 months, the median event-free survival (EFS) was 17·0 months (age 70-80 years, 17·7 months; age above 80 years, 8·6 months; P = 0·002). The median overall survival was 45·1 months (age 70-80, 49·8 months; above 80, 33·3 months; P = 0·003). Amongst those who had seven or more cycles of treatment, those who had a pre-planned switch to bortezomib-thalidomide-dexamethasone (VTD) consolidation had a superior median EFS of 25·4 months, compared with 20·3 months in the CyBorD only group (P = 0·028). This is the largest real-world dataset on the efficacy of CyBorD in the elderly population, and pre-planned switch to VTD was associated with better outcomes.
引用
- Chan H, Chai K, Shih S, et al. Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data. Br J Haematol. 2019. PMID: 31298750. doi:10.1111/bjh.16095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。